Why MedReleaf Corp. Rose About 1% on Thursday

MedReleaf Corp. (TSX:LEAF) rose about 1% on Thursday following a deal to supply Shoppers Drug Mart with its products. What should you do now?

| More on:
You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

What?

Medical cannabis producer MedReleaf Corp. (TSX:LEAF) watched its stock rise about 1% on Thursday following its announcement that it had entered an agreement to supply Shoppers Drug Mart with MedReleaf branded cannabis products.

So what?

Shoppers Drug Mart, a wholly owned subsidiary of Loblaw Companies Limited (TSX:L), is Canada’s leading health, beauty, and convenience retailer with more than 1,300 locations from coast to coast. MedReleaf stated that it expects Shoppers Drug Mart to sell its products online, since current regulations in Canada restrict the sale of medical cannabis in retail pharmacies, but with how fast the cannabis industry is changing, and with legalization expected to occur in 2018, I think there is a very good chance MedReleaf’s products will be available in stores by the end of 2019.

Now what?

Aphria Inc. (TSX:APH) announced a similar deal with Shoppers Drug Mart on December 4, but I think Shoppers Drug Mart and the cannabis industry as a whole are large enough for multiple players. 

MedReleaf’s stock is up more than 101% since I first recommended it on August 15, and I think the best has yet to come for this small cap, because I think marijuana will be legalized in Canada by the end of 2018, which will result in explosive growth in demand.

With all of this being said, I think all Foolish investors seeking exposure to this high-growth industry should strongly consider initiating positions in MedReleaf today.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Joseph Solitro has no position in any stocks mentioned.

More on Investing

Investing

Pitch Braze Ad

This is my excerpt.

Read more »

Investing

KM Throwaway Post

Before Fool Braze Ad Mid-Article-Pitch The sun dipped low on the horizon, casting long, golden shadows across the quiet park.…

Read more »

Investing

Carlos Test Yoast Metadata

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing

KM Ad Test

This is my excerpt.

Read more »

Investing

Test post for affiliate partner mockups

Updated: 9/17/2024. This post was not sponsored. The views and opinions expressed in this review are purely those of the…

Read more »

Investing

Testing Ecap Error

Premium content from Motley Fool Stock Advisor We here at Motley Fool Stock Advisor believe investors should own at least…

Read more »

Investing

TSX Today: Testing the Ad for James

la la la dee dah.

Read more »

Lady holding remote control pointed towards a TV
Investing

2 Streaming Stocks to Buy Now and 1 to Run From

There are streaming stocks on the TSX that are worth paying attention to in 2023 and beyond.

Read more »